Project Grant R03ES038960
- The National Institute of Environmental Health Sciences awarded Auburn University $571,566 for research characterizing the biological effects of engineered nanomaterials on mitochondrial health under the Environmental Health program (CFDA 93.113) on April 20, 2026. The project, titled "Unraveling the Biological Effects of Engineered Nanomaterials from a Mitochondrial Perspective," investigates how gold nanoparticles and other engineered nanomaterials modulate mitochondrial function...
- The National Institute of Environmental Health Sciences, part of the National Institutes of Health under the Department of Health and Human Services, awarded the University of Pittsburgh $127,384 on September 11, 2025, under the Environmental Health program (CFDA 93.113) for research into the dynamics of oxidative DNA demethylation. The award supports a mentored K99/R00 career development grant. During the mentored K99 phase, the candidate will receive training in multiple techniques including...
- The National Institute of Environmental Health Sciences awarded Florida International University $489,258 on April 24, 2026, under the Environmental Health program (CFDA 93.113) to investigate the crosstalk of epitranscriptomic RNA modifications and DNA damage repair mechanisms, with performance through March 31, 2031, at the Miami, Florida campus. The research examines how environmentally induced RNA damage, the epitranscriptomic mark N6-methyladenosine (M6A), and DNA base damage interact on...
- The National Institute of Allergy and Infectious Diseases awarded the University of New Hampshire $1,136,734 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of the transcription factor GLI2 in antibody production and class switch recombination in B cells. The research combines human monoclonal IgM-secreting B cell lines with conditional transgenic mouse models carrying GLI2 deficiency in B cells and hematopoietic cells to...
- The National Institute of Biomedical Imaging and Bioengineering awarded Emory University $217,443 on August 5, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop class-selective chemical probes that distinguish reactive aldehyde signaling in living systems. The research will create a sensing platform capable of discriminating four mechanistically distinct classes of reactive aldehydes—monoaldehydes, α-dicarbonyls,...
- The National Institute of Allergy and Infectious Diseases awarded the University of Alabama at Birmingham $480,853 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Project Grant R01AI195802) to investigate the stability and dynamics of the human anti-carbohydrate antibody repertoire across the lifespan. The research examines how chronic exposure to commensal microbiota-derived glycan determinants shapes the anti-carbohydrate (AC) B cell repertoire....
- The National Institute of General Medical Sciences awarded Auburn University $417,061 on March 23, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop an electrochemical platform for quantitative analysis of cell spheroid models and tissues. The project runs through January 31, 2031, with performance at Auburn, Alabama. The award funds development of a generalizable electrochemical sensing platform combining nucleic acid "bowtie" sensors and...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Michigan $195,000 on August 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to sequence exosome-associated DNA released from activated neutrophils. The research characterizes molecular features of DNA secreted from activated neutrophils during innate immune and inflammatory responses. Recent work has revealed that activated and migrating neutrophils co-release...
- Federal Project Grant Award Summary Vanderbilt University, through its Sponsored Programs Administration division, received a $122,850 Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health program (CFDA 93.113), with an award date of August 1, 2025, and completion date of July 31, 2026. This funding supports research investigating the role of error-prone DNA polymerases in bacterial mutagenesis and the evolution of antibiotic...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of South Alabama a $431,147 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a two-year period from July 1, 2025, through June 30, 2027. The research project, titled "Innate Immune Regulation of Monoclonal Antibody-Induced Infusion Reactions," addresses the mechanisms underlying adverse immune reactions that occur during...
The National Institute of Environmental Health Sciences awarded $156,000 to the University of South Alabama on August 5, 2026, to develop and characterize novel single-domain antibodies (nanobodies) tailored to the NEIL1 and NEIL2 DNA glycosylases under the Environmental Health program (CFDA 93.113). The project addresses barriers to studying NEIL1 and NEIL2, which are central to the base excision repair pathway that protects genome integrity from oxidative DNA damage. These enzymes are expressed at low cellular levels, contain extensive disordered regions, and lack reliable commercial antibody reagents. The award funds two aims: rigorous benchmarking of an existing NEIL1 nanobody panel through biophysical assays and functional testing of glycosylase activity and recruitment upon induced DNA damage; and generation and validation of the first NEIL2-specific nanobodies using the same pipeline. The expected outcome is a set of high-affinity, epitope-defined nanobodies capable of enabling both structural studies and live-cell enzyme tracking. This is a project grant, assistance type R03, which supports innovative research typically conducted over two years. Performance is located in Mobile, Alabama. The period of performance runs through August 4, 2028. The work builds on preliminary NEIL1 nanobody development and institutional seed funding for NEIL2 nanobody feasibility studies already completed at the university.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $156.0k | 8/4/26 |